NCT05822661Not yet recruiting
Impact of Black Seed Oil on Hemodialysis Patients
Evaluation of the Impact of Black Seed Oil on Hemodialysis Patients
Ain Shams UniversityPhase 2ClinicalTrials.govdietary supplement
Study focus
- Disease/Condition
- End Stage Renal Disease
- Drug/Device/Intervention
- Black Seed Oil
- Study type
- Interventional
- Intervention type
- dietary supplement
Sponsor & location
- Primary sponsor
- Ain Shams University
- Location
- Cairo, Egypt
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 22, 2023
- End date
- Apr 23, 2023
- Enrollment
- 60 participants
Primary outcome
serum Endothelin-1 (ET-1) level
Summary
The aim of the study is to evaluate the effect of black seed oil on endothelial dysfunction,
 oxidative stress and quality of life in hemodialysis patients.
ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05822661
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05822661 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ain Shams University and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.